Literature DB >> 23827524

Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral sclerosis.

Daniela Calini1, Lucia Corrado, Roberto Del Bo, Stella Gagliardi, Viviana Pensato, Federico Verde, Stefania Corti, Letizia Mazzini, Pamela Milani, Barbara Castellotti, Cinzia Bertolin, Gianni Sorarù, Cristina Cereda, Giacomo P Comi, Sandra D'Alfonso, Cinzia Gellera, Nicola Ticozzi, John E Landers, Antonia Ratti, Vincenzo Silani.   

Abstract

Mutations in the prion-like domain (PrLD) of hnRNPA1 and A2/B1 genes were recently identified in 2 families with inclusion body myopathy associated with Paget disease of bone, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis, and in ALS patients. These mutations were shown to increase the propensity of hnRNPA1 and A2/B1 proteins, which are TDP-43-binding partners, to self-aggregate. hnRNPA3 protein contains a similar PrLD and was recently described in the p62-positive/TDP-43-negative inclusions in affected tissues of C9orf72-mutated ALS/FTD patients. We screened hnRNPA1, A2/B1, and A3 genes in a cohort of 113 familial ALS (FALS) individuals without mutations in other known ALS-causative genes. We extended our analysis to 108 FALS with mutations in other ALS-associated genes and to 622 sporadic cases by screening specifically the PrLDs of hnRNPA1, A2/B1, and A3. We failed to find variants in each cohort. Our results suggest that mutations in hnRNPA1, A2/B1, and A3 genes are a rare finding in ALS.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALS; Genetics; IBMPFD; Prion-like domain; hnRNP

Mesh:

Substances:

Year:  2013        PMID: 23827524      PMCID: PMC6591723          DOI: 10.1016/j.neurobiolaging.2013.05.025

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  10 in total

Review 1.  Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

Authors:  Giulietta Riboldi; Chiara Zanetta; Michela Ranieri; Monica Nizzardo; Chiara Simone; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2014-05-09       Impact factor: 5.590

2.  Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions.

Authors:  Rohini Raman; Scott P Allen; Emily F Goodall; Shelley Kramer; Lize-Linde Ponger; Paul R Heath; Marta Milo; Hannah C Hollinger; Theresa Walsh; J Robin Highley; Simon Olpin; Christopher J McDermott; Pamela J Shaw; Janine Kirby
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

3.  Amyotrophic Lateral Sclerosis Type 20 - In Silico Analysis and Molecular Dynamics Simulation of hnRNPA1.

Authors:  Bruna Baumgarten Krebs; Joelma Freire De Mesquita
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

4.  Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis.

Authors:  Nadine Bakkar; Tina Kovalik; Ileana Lorenzini; Scott Spangler; Alix Lacoste; Kyle Sponaugle; Philip Ferrante; Elenee Argentinis; Rita Sattler; Robert Bowser
Journal:  Acta Neuropathol       Date:  2017-11-13       Impact factor: 17.088

5.  Heterogeneous Nuclear Ribonucleoprotein E2 (hnRNP E2) Is a Component of TDP-43 Aggregates Specifically in the A and C Pathological Subtypes of Frontotemporal Lobar Degeneration.

Authors:  Wejdan Kattuah; Boris Rogelj; Andrew King; Christopher E Shaw; Tibor Hortobágyi; Claire Troakes
Journal:  Front Neurosci       Date:  2019-06-04       Impact factor: 4.677

6.  The transcript expression levels of HNRNPM, HNRNPA0 and AKAP17A splicing factors may be predictively associated with ageing phenotypes in human peripheral blood.

Authors:  Benjamin P Lee; Luke C Pilling; Stefania Bandinelli; Luigi Ferrucci; David Melzer; Lorna W Harries
Journal:  Biogerontology       Date:  2019-07-10       Impact factor: 4.277

7.  Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy.

Authors:  Hong Joo Kim; Payam Mohassel; Sandra Donkervoort; Lin Guo; Kevin O'Donovan; Maura Coughlin; Xaviere Lornage; Nicola Foulds; Simon R Hammans; A Reghan Foley; Charlotte M Fare; Alice F Ford; Masashi Ogasawara; Aki Sato; Aritoshi Iida; Pinki Munot; Gautam Ambegaonkar; Rahul Phadke; Dominic G O'Donovan; Rebecca Buchert; Mona Grimmel; Ana Töpf; Irina T Zaharieva; Lauren Brady; Ying Hu; Thomas E Lloyd; Andrea Klein; Maja Steinlin; Alice Kuster; Sandra Mercier; Pascale Marcorelles; Yann Péréon; Emmanuelle Fleurence; Adnan Manzur; Sarah Ennis; Rosanna Upstill-Goddard; Luca Bello; Cinzia Bertolin; Elena Pegoraro; Leonardo Salviati; Courtney E French; Andriy Shatillo; F Lucy Raymond; Tobias B Haack; Susana Quijano-Roy; Johann Böhm; Isabelle Nelson; Tanya Stojkovic; Teresinha Evangelista; Volker Straub; Norma B Romero; Jocelyn Laporte; Francesco Muntoni; Ichizo Nishino; Mark A Tarnopolsky; James Shorter; Carsten G Bönnemann; J Paul Taylor
Journal:  Nat Commun       Date:  2022-04-28       Impact factor: 17.694

8.  Isolated inclusion body myopathy caused by a multisystem proteinopathy-linked hnRNPA1 mutation.

Authors:  Rumiko Izumi; Hitoshi Warita; Tetsuya Niihori; Toshiaki Takahashi; Maki Tateyama; Naoki Suzuki; Ayumi Nishiyama; Matsuyuki Shirota; Ryo Funayama; Keiko Nakayama; Satomi Mitsuhashi; Ichizo Nishino; Yoko Aoki; Masashi Aoki
Journal:  Neurol Genet       Date:  2015-09-24

9.  Heterogeneous ribonuclear protein A3 (hnRNP A3) is present in dipeptide repeat protein containing inclusions in Frontotemporal Lobar Degeneration and Motor Neurone disease associated with expansions in C9orf72 gene.

Authors:  Yvonne S Davidson; Louis Flood; Andrew C Robinson; Yoshihiro Nihei; Kohji Mori; Sara Rollinson; Anna Richardson; Bridget C Benson; Matthew Jones; Julie S Snowden; Stuart Pickering-Brown; Christian Haass; Tammaryn Lashley; David M A Mann
Journal:  Acta Neuropathol Commun       Date:  2017-04-21       Impact factor: 7.801

10.  Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation.

Authors:  Danique Beijer; Hong Joo Kim; Lin Guo; Kevin O'Donovan; Inès Mademan; Tine Deconinck; Kristof Van Schil; Charlotte M Fare; Lauren E Drake; Alice F Ford; Andrzej Kochański; Dagmara Kabzińska; Nicolas Dubuisson; Peter Van den Bergh; Nicol C Voermans; Richard Jlf Lemmers; Silvère M van der Maarel; Devon Bonner; Jacinda B Sampson; Matthew T Wheeler; Anahit Mehrabyan; Steven Palmer; Peter De Jonghe; James Shorter; J Paul Taylor; Jonathan Baets
Journal:  JCI Insight       Date:  2021-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.